top of page
ONCOLOGY BUSINESS REVIEW
The Rise — and fall? — of Avastin
A look at the FDA's controversial review of Avastin's indication for advanced metastatic breast cancer.
Taking it Personal: When to Add Biomarkers to Treatment Guidelines
The role of diagnostics in the future of cancer drug development is central to the personalization of therapy. But numerous issues surround the incorporation of biomarkers into treatment guidelines.
Targeting Therapy: New Approaches to Finding the Next Great Cancer Drug
The next big breakthrough depends not only on the lab bench but also—and perhaps more so—on the willingness of all those involved to work cooperatively and take greater risks.
The Future of the Present: A look at current and proposed state legislation to regulate and disclose gifts
New state laws to restrict and monitor the giving of gifts from pharma reps to doctors are popping up across the country.
Behind Closed Network Doors: Oral cancer drugs and the rise of specialty pharmacy
New state laws to restrict and monitor the giving of gifts from pharma reps to doctors are popping up across the country.
bottom of page